Description
Canaan (Canaan Partners) is a premier global venture capital firm with over $6 billion under management. As of 2026, the firm is actively deploying its 13th flagship fund (Canaan XIII), a $850 million vehicle focused on early-stage technology and healthcare.
-
Seed & Series A: Canaan is primarily an early-stage lead investor. They often write the first institutional check for founders.
-
Growth: They provide follow-on capital and lead Series B or C rounds for high-performing companies within and outside their initial portfolio
As a traditional institutional VC, Canaan does not have a "batch" application process or a public accelerator form.
-
Engagement: Founders typically secure meetings through warm introductions from their professional network or by reaching out to specific partners covering their sector.
-
Focus Areas: For 2026, Canaan is heavily focused on Generative AI infrastructure, Cloud security, Fintech infrastructure, and Biopharmaceuticals (specifically oncology and immunology).